So it's a done deal: after months, if not years, of promise and hope, New York has legalized recreational marijuana (it did so with medical pot in 2014). Three noted cannabis companies are already operating in the Empire State -- Curaleaf Holdings (OTC: CURLF), Cresco Labs (OTC: CRLBF), and Columbia Care (OTC: CCHWF). Of the trio, two are really worth watching as New York flips the adult-use switch.
In this segment from Motley Fool Live recorded on May 21, veteran Fool contributor Eric Volkman zeroes in on the two in a discussion with healthcare and cannabis bureau chief Corinne Cardina.
Here's The Marijuana Stock You've Been Waiting For
A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.
And make no mistake – it is coming.
Cannabis legalization is sweeping over North America – 15 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018.
And one under-the-radar Canadian company is poised to explode from this coming marijuana revolution.
Because a game-changing deal just went down between the Ontario government and this powerhouse company...and you need to hear this story today if you have even considered investing in pot stocks.
Simply click here to get the full story now.
Corinne Cardina: So are there any pot stocks that already have a footprint in New York from the medical program, and that might have a first-mover advantage?
Eric Volkman: Yeah, there are several. There's a couple of candidates.
Basically, we're looking at three companies. You've got Curaleaf Holdings, which is a multi-state operator (MSO) that, as the term implies, is active in a bunch of states; basically, it's the biggest MSO in America. Cresco Labs, which is an ambitious company out of Illinois, and then we have Columbia Care, which I consider to be kind of a dark horse. They have to be in the mix, though, because they are actually based in New York City unlike the other two. Curaleaf is based in Massachusetts.
Curaleaf and Cresco have four dispensaries apiece. As you say because at the moment or prior to this legalization, New York was purely a medical marijuana market. Even now those dispensaries are just selling medical product -- you can't buy recreational there. The first two companies that I mentioned, Curaleaf and Cresco, they have a leg up because of that.
Out of the two, if we are just talking of pure presence in New York right now, the edge has to go to Curaleaf because they have a grow facility. They have a place from which they can natively supply their [New York] dispensaries. But a lot can change, and especially for waiting like a year for the switch to be flipped on the actual pot market, other companies can jump in and I'm sure they will.
Like, for example, Cresco. They have a fairly hot rivalry with another Illinois vertically integrated weed company called Green Thumb Industries. They might be casting a hungry eye on New York too. Right now, though, if you are going to take any company with a head start, Curaleaf and Cresco are probably the two to watch.
Columbia Care, I don't think so much even though they have four dispensaries in the state, like the other two companies. To me, they seem more interested in states outside New York. Recently they signed a $240 million deal for a company called Green Leaf Medical. [So] they're like a Mid-Atlantic company. They're active in Ohio, Virginia, Pennsylvania, and Maryland.
I think their focus is elsewhere. I mean, I haven't heard the company pronounce too much on their ambitions, but it seems like they might be ceding the New York market.
So at the end of the day, Curaleaf and Cresco probably are the two at this early stage I would keep an eye on.
Corinne Cardina has no position in any of the stocks mentioned. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Cresco Labs Inc. and Green Thumb Industries. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.